Cipla aiming top-line of $1 billion from domestic market in FY19

11 Jun 2018 Evaluate

Cipla is bullish on growth and is aiming for $1 billion consolidated revenue for the domestic market in FY19. The country’s fourth-largest drug maker reported revenues of Rs 15,219 crore, growing 6 per cent, with income from the India operations seeing a 6.3 per cent jump at Rs 5,687 crore in FY18.

The drug maker is expecting the in-licensing deals with innovator companies, focus on certain therapeutic segments and sales force productivity optimisation measures to aid growth in India.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1447.60 -18.45 (-1.26%)
13-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.80
Dr. Reddys Lab 1190.35
Cipla 1447.60
Zydus Lifesciences 900.25
Lupin 2176.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×